drugsTreatmentPhase 3

Ivospemin

Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.

Ivospemin (SBP-101) is a small-molecule drug developed by Panbela Therapeutics. The sponsor describes its target as polyamine metabolism, which OnCo does not yet have a target page for. The sponsor states: A small-molecule polyamine metabolic inhibitor administered by subcutaneous injection. ClinicalTrials.gov describes the intervention as: small molecule polyamine metabolic inhibitor for subcutaneous injection. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05254171 (Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer), in pancreatic ductal adenocarcinoma. The largest, NCT05254171, plans to enrol 600 participants with primary completion expected 2026-08-29. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

Modality

small molecule

Mechanism

A small-molecule polyamine metabolic inhibitor administered by subcutaneous injection.

Brand / code

SBP-101

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Ivospemin

intervention: Ivospemin

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.